SANUWAVE Q1 2025 slides: revenue surges 61%, company turns profitable

SANUWAVE Health (SNWV) reported strong Q1 2025 results, with revenue increasing 61% year-over-year to $9.3 million and achieving operating income of $1.0 million, a $1.1 million improvement from the prior year. The company's growth is driven by increased UltraMist system installations and consumables sales, with system sales up 145% and consumables revenue up 43% year-over-year. SANUWAVE projects Q2 revenue growth of 40-50% and full-year revenue of $48-50 million, citing the industry's shift toward evidence-based medicine as a key driver.

Analysis

SANUWAVE Health (SNWV) demonstrated significant financial improvement in its first quarter of fiscal year 2025, reporting a 61% year-over-year revenue increase to $9.3 million and achieving operating income of $1.0 million, a substantial turnaround from a $1.1 million operating loss in Q1 2024. This robust performance was primarily driven by a 145% surge in UltraMist system sales, with 98 units sold, and a 43% rise in recurring consumables revenue, reflecting growing market adoption with 1,145 systems now deployed. Gross profit increased by 76% to $7.4 million, leading to a gross margin expansion of 642 basis points to 79.0%, showcasing improved operational efficiency as revenue growth outpaced the 21% increase in operating expenses, which included $295,000 in Nasdaq listing fees. Although the company reported a net loss of $5.68 million, this was largely due to a $4.9 million non-cash change in the fair value of derivative liabilities; adjusted EBITDA painted a more positive operational picture, reaching $2.32 million compared to a negative $59,000 in the prior-year period. SANUWAVE has issued optimistic guidance, projecting Q2 2025 revenue growth of 40-50% and full-year 2025 revenue between $48-50 million, representing a 47-53% increase over FY 2024, supported by industry shifts towards evidence-based medicine and the company's capital-light business model.

Key Decisions for Investors

• Investors should consider the strong Q1 2025 revenue acceleration and the pivotal shift to operating profitability as significant positive developments for SANUWAVE.
• The continued growth trajectory of UltraMist system placements and, crucially, the expansion of high-margin recurring consumables revenue, will be critical metrics to monitor in assessing the company's ability to meet its ambitious fiscal 2025 revenue targets of $48-50 million.
• While the reported net loss was significantly impacted by non-cash derivative liability adjustments, future financial reports should be scrutinized for progress towards sustained GAAP net profitability and evidence of continued operational leverage as the company scales.